Cullgen is also evaluating CG009301, a GSPT1 degrader for the treatment of blood cancers including relapsed/refractory acute myeloid leukemia (AML), higher-risk myelodysplastic syndrome (HR-MDS), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback